Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Mean corpuscular volume as a marker for adherence to zidovudine-containing therapy in HIV-infected adults
Open AIDS Journal, Volume 6, No. 1, Year 2012
Notification
URL copied to clipboard!
Description
Objectives: To assess whether mean corpuscular volume (MCV) is useful in detecting non-adherence to AZT-containing therapy. Design: Observational study within randomised controlled trial. Methods: We combined data from two treatment arms in SPARTAC, an RCT of short-course cART in primary HIV infection, classifying participants as responders (HIV-RNA decrease ≥1 log1 0 or reaching <400copies/ml) or non-responders following cART initiation. We assessed the sensitivity and specificity of using different percentage increases in MCV for accurately differentiating between responders and non-responders. We further examined changes in MCV levels up to 24 weeks after protocol-indicated cART cessation. Results: Of 119 participants included in this analysis, 73 (61%) were women, 71 of whom were randomised in Africa. Ninety-eight (88%) and 84 (85%) were classified as responders at 4 and 12 weeks respectively following cART initiation. MCV increased by a mean 3% and 1% at week 4, and 14% and <1% at 12 weeks for responders and non-responders. A 2% MCV increase at 4 weeks had 62% sensitivity and specificity for identifying virological response. At 12 weeks, an 8% increase had 89% sensitivity and specificity. In responders, MCV remained lower for individuals in African compared to non-African sites throughout and rose from 85 vs 90 fL at cART start to 96 vs 103 fL at 12 weeks post-initiation then fell to 88 vs 93 fL and 86 vs 89 fL at 12 and 48 weeks post-cessation. Conclusion: In low-income countries, where HIV RNA may be unavailable, 12-weekly MCV measurements may be useful in monitoring adherence to AZT-containing regimens. © Mugisha et al.
Authors & Co-Authors
Mugisha, Joseph Okello
United Kingdom
Mrc/uvri Uganda Research Unit on Aids
Donegan, Katherine L.
United Kingdom, London
Mrc Clinical Trials Unit
Fidler, Sarah J.
United Kingdom, London
Imperial College London
Ramjee, Gita A.
South Africa, Tygerberg
South African Medical Research Council
Hodson, Andrew
United Kingdom, London
Imperial College London
Dunn, David T.
United Kingdom, London
Mrc Clinical Trials Unit
Porter, Kholoud
United Kingdom, London
Mrc Clinical Trials Unit
Kaleebu, Pontiano P.
United Kingdom
Mrc/uvri Uganda Research Unit on Aids
Statistics
Citations: 11
Authors: 8
Affiliations: 4
Identifiers
Doi:
10.2174/1874613601206010045
e-ISSN:
18746136
Research Areas
Infectious Diseases
Study Design
Randomised Control Trial
Study Approach
Quantitative
Participants Gender
Female